Last edition
News about
Inimmune Begins Phase 2 Trial of INI-2004 for Allergic Rhinitis
The randomised, placebo-controlled allergen chamber study will evaluate the safety and efficacy of Inimmune’s immunotherapy candidate INI-2004 in patients exposed to controlled ragweed allergens.
Acesion Pharma Begins Phase-II Trial of AP31969 in Atrial Fibrillation
The Phase-II study of AP31969 by Acesion Pharma will evaluate the efficacy and safety of AP31969, a first-in-class oral SK ion channel inhibitor, in reducing atrial fibrillation burden using continuous cardiac rhythm monitoring.
ABS Bio Buys Cureline, Enhancing Biospecimen Access and Execution
The add-on acquisition of Cureline by ABS Bio, a 3 Boomerang portfolio company, expands ABS Bio’s capabilities, geographic reach and client base while strengthening its end-to-end biospecimen services.
Merck Completes Acquisition of Cidara Therapeutics to Strengthen Influenza Pipeline
Merck, known as MSD outside the United States and Canada, has announced the successful completion of its cash tender offer, through a subsidiary, to acquire Cidara Therapeutics, Inc.
Bayer's Monsanto Unit Sues Major COVID Vaccine Makers Over mRNA Patent Infringement
German chemical and life sciences company Bayer, through its Monsanto subsidiary, has filed a series of patent infringement lawsuits against several major COVID-19 vaccine manufacturers, alleging unauthorised use of its messenger RNA (mRNA) technology in the development of coronavirus vaccines.
Dr Reddy's Launches Recombinant Hepatitis E Vaccine Hevaxin in India
According to Dr Reddy’s, clinical studies show that Hevaxin offers protective efficacy, durable immunity, and a favourable immune response, supported by an established safety and tolerability profile.
Biocon Biologics to Showcase Keytruda and Two New Oncology Biosimilars at JPM 2026
Biocon Biologics, the biosimilars arm of Biocon Ltd, is set to introduce three new oncology biosimilars, including a biosimilar of pembrolizumab (Keytruda), at the J.P. Morgan Healthcare Conference 2026 in San Francisco.
Prokaryotics, Basilea Partner to Develop First-in-Class Broad-Spectrum Antifungal
Partnership between Prokaryotics and Basilea will develop broad-spectrum antifungal treatment that targets life-threatening invasive fungal infections.
Sectra Enters Japan's Digital Pathology Market with Kameda Medical Centre Project
Sectra brings AI-enabled digital pathology workflows to Kameda Medical Centre in partnership with Matsunami Glass.
Bayer Secures Breakthrough Status for Sevabertinib in HER2 NSCLC
US FDA and China’s CDE granted the designation for sevabertinib as a potential first-line therapy in advanced HER2-mutant non-small cell lung cancer.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy